An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE™ 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)
Latest Information Update: 01 Jul 2023
At a glance
- Drugs Cenegermin (Primary)
- Indications Keratitis
- Focus Therapeutic Use
- Acronyms DEFENDO
- Sponsors Dompe Farmaceutici
- 11 Apr 2022 Status changed from active, no longer recruiting to completed.
- 07 Jan 2022 Planned End Date changed from 1 Aug 2021 to 1 Mar 2022.
- 07 Jan 2022 Status changed from recruiting to active, no longer recruiting.